A Phase 1b/2 Study to Evaluate D-1553 in Combination Therapy in Subjects With Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and
Efficacy of D-1553 Combination Therapy in Subjects with KRAS G12C-mutated Locally Advanced or
Metastatic Non-Small Cell Lung Cancer.